Treatment Response Evaluation in Hepatic Tumors using CT and MRI: Road Map for Radiologist

2017 ◽  
pp. 49-62
Author(s):  
A. V. Fedash ◽  
K. H. Lomovtseva ◽  
E. V. Kondrat'ev ◽  
I. A. Blohin ◽  
Yu. S. Galchina

The number of available methods for hepatic tumor treatment is steadily increasing. Except traditional surgical resection and systemic chemotherapy there are a lot of effective and increasingly used local methods such as Radiofrequency ablation, cryodestruction, transarterial chemoembolization. Radiologist should be able to assess treatment response and evaluate prognosis. We present review of literature on various systems for hepatic tumor treatment response evaluation. WHO, RECIST 1.0, RECIST 1.1, mRECIST and Choi criteria are thoroughly explained in terms of benefits and drawbacks. Also, texture analysis and diffusion-weighted imaging are discussed.

PET Clinics ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. 201-217 ◽  
Author(s):  
Benjamin M. Ellingson ◽  
Wei Chen ◽  
Robert J. Harris ◽  
Whitney B. Pope ◽  
Albert Lai ◽  
...  

2020 ◽  
Vol 13 (3) ◽  
pp. 228-237
Author(s):  
Angelo Castello ◽  
Sabrina Rossi ◽  
Egesta Lopci

Background: Metabolic information provided by 18F-FDG PET/CT are useful for initial staging, therapy planning, response evaluation, and to a lesser extent for the follow-up of non-small cell lung cancer (NSCLC). To date, there are no established clinical guidelines in treatment response and early detection of recurrence. Objective: To provide an overview of 18F-FDG PET/CT in NSCLC and in particular, to discuss its utility in treatment response evaluation and restaging of lung cancer. Methods: A comprehensive search was used based on PubMed results. From all studies published in English those that explored the role of 18F-FDG PET/CT in the treatment response scenario were selected. Results: Several studies have demonstrated that modifications in metabolic activity, expressed by changes in SUV both in the primary tumor as well as in regional lymph nodes, are associated with tumor response and survival. Beside SUV, other metabolic parameters (i.e. MTV, TLG, and percentage changes) are emerging to be helpful for predicting clinical outcomes. Conclusion: 18F-FDG parameters appear to be promising factors for evaluating treatment response and for detecting recurrences, although larger prospective trials are needed to confirm these evidences and to determine optimal cut-off values.


Sign in / Sign up

Export Citation Format

Share Document